1. GR Lichtenstein et al. Management of Crohn’s disease in adults. Am J Gastroenterol 2009; 104:465.
2. A Kornbluth et al. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105:501.
3. C Campregher and C Gasche. Aminosalicylates. Best Pract Res Clin Gastroenterol 2011; 25:535.
4. Once-daily mesalamine (Lialda) for ulcerative colitis. Med Lett Drugs Ther 2007; 49:25.
5. Encapsulated mesalamine granules (Apriso) for ulcerative colitis. Med Lett Drugs Ther 2009; 51:38.
6. P Marteau et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54:960.
7. AC Ford et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:617.
8. KJ Khan et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106:661.
9. GT Ho et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24:319.
10. AH Steinhart et al. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2003; (4): CD000301.
11. Budesonide (Entocort EC) for Crohn’s disease. Med Lett Drugs Ther 2002; 44:6.
12. AG Fraser et al. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50:485.
13. JF Colombel et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362:1383.
14. L Peyrin-Biroulet et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141:1621.
15. L Beaugerie et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374:1617.
16. A Thai and T Prindiville. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohn’s Colitis 2010; 4:511.
17. FDA drug safety communication: safety review update on reports of hepatosplenic T-cell lymphoma in adolescents and young adults receiving tumor necrosis factor (TNF) blockers, azathioprine, and/or mercaptopurine. Available at http://www.fda.gov. Accessed February 7, 2012.
18. S Vermeire et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007; 56:1226.
19. BG Feagan et al. Methotrexate for the treatment of Crohn’s disease. N Engl J Med 1995; 332:292.
20. BG Feagan et al. Acomparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. N Engl J Med 2000; 342:1627.
21. S Lichtiger et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841.
22. M Naganuma et al. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol 2011; 46:129.
23. H Ogata et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55:1255.
24. Certolizumab (Cimzia) for Crohn’s disease. Med Lett Drugs Ther 2008; 50:81.
25. D Tracey et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244.
26. GR Lichtenstein et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130:935.
27. SR Targan et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337:1029.
28. SB Hanauer et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359:1541.
29. DH Present et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340:1398.
30. BE Sands et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350:876.
31. M Regueiro et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009; 136:441.
32. JF Colombel et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132:52.
33. S Schreiber et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007; 357:239.
34. L Peyrin-Biroulet et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6:644.
35. WJ Sandborn et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146:829.
36. S Danese et al. Successful induction of clinical response and remission with certolizumab pegol in Crohn’s disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use. Inflamm Bowel Dis 2008; 14:1168.
37. P Rutgeerts et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462.
38. W Reinisch et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60:780.
39. WJ Sandborn et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142:257.
40. WJ Sandborn et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005; 353:1912.
41. SR Targan et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology 2007; 132:1672.
42. Natalizumab (Tysabri) for Crohn's disease. Med Lett Drugs Ther 2008; 50:34.
43. US Food & Drug Administration. FDA News Release: FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri. January 20, 2012. Available at: http://www.fda.gov. Accessed February 7, 2012.
44. Probiotics. Med Lett Drugs Ther 2007; 49:66.
45. JP Buts and N De Keyser. Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 2006; 51:1485.
46. MH Floch and DC Montrose. Use of probiotics in humans: an analysis of the literature. Gastroenterol Clin North Am 2005; 34:547.
47. BJ Rembacken et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354:635.
48. W Kruis et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissile 1917 is as effective as with standard mesalazine. Gut 2004; 53:1617.
49. MA Zocco et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23:1567.
50. P Gionchetti et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305.